CA1073355A - Influenza vaccine containing purified neuraminidase antigen and method of using the same - Google Patents
Influenza vaccine containing purified neuraminidase antigen and method of using the sameInfo
- Publication number
- CA1073355A CA1073355A CA243,608A CA243608A CA1073355A CA 1073355 A CA1073355 A CA 1073355A CA 243608 A CA243608 A CA 243608A CA 1073355 A CA1073355 A CA 1073355A
- Authority
- CA
- Canada
- Prior art keywords
- vaccine
- influenza
- antigen
- virus
- neuraminidase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 108010006232 Neuraminidase Proteins 0.000 title claims abstract description 57
- 102000005348 Neuraminidase Human genes 0.000 title claims abstract description 57
- 239000000427 antigen Substances 0.000 title claims abstract description 40
- 102000036639 antigens Human genes 0.000 title claims abstract description 40
- 108091007433 antigens Proteins 0.000 title claims abstract description 40
- 229960003971 influenza vaccine Drugs 0.000 title claims abstract description 13
- 238000000034 method Methods 0.000 title claims description 20
- 241000700605 Viruses Species 0.000 claims abstract description 56
- 229960005486 vaccine Drugs 0.000 claims abstract description 33
- 241000712461 unidentified influenza virus Species 0.000 claims abstract description 30
- 230000009260 cross reactivity Effects 0.000 claims abstract description 13
- 206010022000 influenza Diseases 0.000 claims abstract description 10
- 241001465754 Metazoa Species 0.000 claims description 23
- 230000008569 process Effects 0.000 claims description 11
- 208000015181 infectious disease Diseases 0.000 claims description 8
- 230000001524 infective effect Effects 0.000 claims description 4
- 230000004523 agglutinating effect Effects 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 abstract description 4
- 241000699670 Mus sp. Species 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 101710154606 Hemagglutinin Proteins 0.000 description 9
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 9
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 9
- 101710176177 Protein A56 Proteins 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 230000003053 immunization Effects 0.000 description 8
- 238000002649 immunization Methods 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 239000000185 hemagglutinin Substances 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 5
- 241000726306 Irus Species 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 241000206607 Porphyra umbilicalis Species 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 210000003837 chick embryo Anatomy 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000518994 Conta Species 0.000 description 1
- INLIXXRWNUKVCF-JTQLQIEISA-N Gly-Gly-Tyr Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 INLIXXRWNUKVCF-JTQLQIEISA-N 0.000 description 1
- 229940124873 Influenza virus vaccine Drugs 0.000 description 1
- SOWBFZRMHSNYGE-UHFFFAOYSA-N Monoamide-Oxalic acid Natural products NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000006193 diazotization reaction Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 108010010096 glycyl-glycyl-tyrosine Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/541,512 US4029763A (en) | 1974-08-05 | 1975-01-16 | Influenza vaccine containing purified neuraminidase antigen and method of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1073355A true CA1073355A (en) | 1980-03-11 |
Family
ID=24159889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA243,608A Expired CA1073355A (en) | 1975-01-16 | 1976-01-15 | Influenza vaccine containing purified neuraminidase antigen and method of using the same |
Country Status (7)
| Country | Link |
|---|---|
| AU (1) | AU507149B2 (enrdf_load_stackoverflow) |
| BE (1) | BE837603A (enrdf_load_stackoverflow) |
| CA (1) | CA1073355A (enrdf_load_stackoverflow) |
| FR (1) | FR2297635A1 (enrdf_load_stackoverflow) |
| GB (1) | GB1536475A (enrdf_load_stackoverflow) |
| NL (1) | NL7600443A (enrdf_load_stackoverflow) |
| PH (1) | PH13837A (enrdf_load_stackoverflow) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2483779A1 (fr) | 1980-06-05 | 1981-12-11 | Synthelabo | Procede pour isoler des antigenes glycoproteiques viraux et son application a la preparation de vaccins |
-
1976
- 1976-01-09 AU AU10163/76A patent/AU507149B2/en not_active Expired
- 1976-01-15 CA CA243,608A patent/CA1073355A/en not_active Expired
- 1976-01-15 BE BE163545A patent/BE837603A/xx not_active IP Right Cessation
- 1976-01-15 PH PH17976A patent/PH13837A/en unknown
- 1976-01-15 FR FR7600974A patent/FR2297635A1/fr active Granted
- 1976-01-16 GB GB1722/76A patent/GB1536475A/en not_active Expired
- 1976-01-16 NL NL7600443A patent/NL7600443A/xx not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| FR2297635B1 (enrdf_load_stackoverflow) | 1980-06-27 |
| AU507149B2 (en) | 1980-02-07 |
| FR2297635A1 (fr) | 1976-08-13 |
| PH13837A (en) | 1980-10-16 |
| BE837603A (fr) | 1976-05-03 |
| AU1016376A (en) | 1977-07-14 |
| NL7600443A (nl) | 1976-07-20 |
| GB1536475A (en) | 1978-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0733113B1 (en) | Influenza vaccine | |
| Chambers et al. | Protection of chickens from lethal influenza infection by vaccinia-expressed hemagglutinin | |
| US4029763A (en) | Influenza vaccine containing purified neuraminidase antigen and method of using the same | |
| Laver et al. | Preparation and immunogenicity of an influenza virus hemagglutinin and neuraminidase subunit vaccine | |
| USRE44916E1 (en) | Canine influenza virus and related compositions and methods of use | |
| US4009258A (en) | Influenza vaccine containing a recombinant, antigenically hybridized virus and method of using the same | |
| EP0480949B1 (en) | Production of virus and purification of viral envelope proteins for vaccine use | |
| US12303560B2 (en) | Recombinant bovine immunodeficiency virus-like particles comprising an influenza HA transmembrane domain and C-terminus | |
| Ben Ahmeida et al. | The IgA and subclass IgG responses and protection in mice immunised with influenza antigens administered as ISCOMS, with FCA, ALH or as infectious virus | |
| CN103228293A (zh) | 用于在哺乳动物中预防和治疗金迪普拉病毒感染的疫苗制剂 | |
| Virelizier et al. | The role of humoral immunity in host defence against influenza A infection in mice | |
| Park et al. | Preparation and immunogenicity of influenza virus-like particles using nitrocellulose membrane filtration | |
| WO1993015763A1 (en) | Vaccinal polypeptides | |
| Hocart et al. | Preparation and characterization of a purified influenza virus neuraminidase vaccine | |
| CA1073355A (en) | Influenza vaccine containing purified neuraminidase antigen and method of using the same | |
| CA1152895A (en) | Process for the preparation of novel influenza virus strains and influenza virus vaccines containing them | |
| WO1994006468A1 (en) | Recombinant influenza virus vaccine compositions | |
| RU2186111C2 (ru) | Рекомбинантная нейраминидаза гриппа типа na 2 (варианты) | |
| Masurel et al. | Vaccination and protection experiments in mice with the human A-1957 and A-1968 strains, and the Equi-2 strain of influenza virus | |
| Arora | Purified viral neuraminidase vaccine to control influenza | |
| KR101753978B1 (ko) | 고병원성 조류 인플루엔자(h5n1) 및 뉴캣슬병 바이러스 융합 바이러스 유사 입자 백신 및 이를 이용한 백신 | |
| Bottex et al. | Comparative immunogenicity of live influenza viruses and their solubilized neuraminidases: results of mouse protection experiments | |
| CN101365481B (zh) | 犬流感病毒及相关组合物和使用方法 | |
| USED | Moscow VOPROSY VIRUSOLOGII in Russian No 1, Jan-Feb 82 (manuscript received 25 Feb 81) pp 5-11 [Article by VI Kostyukov, AI Yarov and Ye. G. Zezerov][Text] Live and killed vaccines are used extensively in current specific prevention of viral infections. In many cases, the use of a number of vaccines | |
| EA042635B1 (ru) | Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |